Vaccines have made it possible to eradicate the scourge of smallpox, promise the same for polio, and have profoundly reduced the threat posed by other diseases such as whooping cough, measles, and meningitis.
What is next? There are many pathogens, autoimmune diseases, and cancers that may be promising targets for vaccine research and development.
This volume provides an analytic framework and quantitative model for evaluating disease conditions that can be applied by those setting priorities for vaccine development over the coming decades. The committee describes an approach for comparing potential new vaccines based on their impact on morbidity and mortality and on the costs of both health care and vaccine development. The book examines:
The committee provides a way to compare different forms of illness and set vaccine priorities without assigning a monetary value to lives. Their recommendations will be important to anyone involved in science policy and public health planning: policymakers, regulators, health care providers, vaccine manufacturers, and researchers.
Table of Contents
|Progress in Vaccine Development||17-38|
|Considerations of Candidate Vaccines||39-52|
|Overview of Analytic Approach and Results||53-92|
|Review of the Analytical Model||93-108|
|Ethical Considerations and Caveats||109-122|
|Appendix 1: Borrelia burgdorferi||143-148|
|Appendix 2: Chlamydia||149-158|
|Appendix 3: Coccidioides Immitis||159-164|
|Appendix 4: Cytomegalovirus||165-172|
|Appendix 5: Enterotoxigenic E. coli||173-176|
|Appendix 6: Epstein-Barr Virus||177-180|
|Appendix 7: Helicobacter pylori||181-188|
|Appendix 8: Hepatitis C||189-194|
|Appendix 9: Herpes Simplex Virus||195-206|
|Appendix 10: Histoplasma capsulatum||207-212|
|Appendix 11: Human Paillomavirus||213-222|
|Appendix 12: Influenza A and B||223-232|
|Appendix 13: Insulin-Dependent Diabetes Mellitus||233-238|
|Appendix 14: Melanoma||239-244|
|Appendix 15: Multiple Sclerosis||245-250|
|Appendix 16: Mycobacterium tuberculosis||251-256|
|Appendix 17: Neisseria gonnorrhea||257-266|
|Appendix 18: Neisseria meningitidis||267-272|
|Appendix 19: Parainfluenza Virus||273-278|
|Appendix 20: Respiratory Syncytial Virus||279-284|
|Appendix 21: Rheumatoid Arthritis||285-290|
|Appendix 22: Rotavirus||291-294|
|Appendix 23: Shigella||295-298|
|Appendix 24: Streptococcus, Group A||299-304|
|Appendix 25: Streptococcus, Group B||305-312|
|Appendix 26: Streptococcus pneumoniae||313-322|
|Appendix 27: Information on accessing Electronic Spreadsheets||323-324|
|Appendix 28: Summary of Workshops||325-434|
|Appendix 29: Questions Posed to Outside Experts and List of Responders||435-442|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Vaccines for the 21st Century: A Tool for Decisionmaking...